Colgate-Palmolive Co. director Lorrie M. Norrington acquired 300 shares of Common Stock on October 1, 2026, at $87.42 per share. The shares were directly held, bringing her reported direct position to 43,310 shares after the transaction. The transaction represented a portion of her annual cash retainer deferred to a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.
Colgate-Palmolive director Brian Newman acquired 214 shares of common stock on October 1, 2026, at a reported $87.42 per share. The acquisition reflects a portion of his annual cash retainer deferred to a stock unit account under the Deferred Compensation Plan for Non-Employee Directors. He directly held 8,058 shares following the acquisition and reported 36 shares indirectly through a Family Trust.
Colgate-Palmolive director John P. Bilbrey acquired 271 common shares on October 1, 2026, at a reported $87.42 per share. The acquisition represented a portion of his annual cash retainer deferred to a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.
COLGATE PALMOLIVE CO (CL) reported that Chairman, President & CEO Noel R. Wallace received equity awards on September 16, 2026. He was granted 205,197 stock options to buy Common Stock at an exercise price of $87.02 per share, expiring September 16, 2036, under the company’s incentive compensation plan; these options become exercisable in equal annual installments over three years beginning on the first anniversary of the grant date. He also received 29,649 restricted stock units, which vest in equal one-third installments on each of the first, second and third anniversaries of the grant date. Following these awards, he holds 379,700 shares of Common Stock directly, plus indirect holdings of 54,868 shares through the issuer’s 401(k) plan trustee, 52,000 shares through a spouse trust, and 335 shares through another trust. No Rule 10b5-1 trading plan is reported for these grants.
COLGATE PALMOLIVE CO (CL) reported that Shane Grant, COO, Americas, received new equity awards on September 16, 2026. He was granted stock options for 50,902 shares of common stock at an exercise price of $87.02 per share, expiring September 16, 2036, vesting in one‑third increments beginning on the first anniversary of the grant date. He also received a restricted stock unit award covering 7,355 shares, which vests in three equal annual installments on the first, second and third anniversaries of the grant date. Following these awards, he directly holds 79,503 shares of common stock and 50,902 stock options; no Rule 10b5‑1 trading plan is reported.
COLGATE PALMOLIVE CO (CL) reports that Chief Operating Officer Panagiotis Tsourapas received equity awards on September 16, 2026. He was granted 31,814 stock options to buy common stock at an exercise price of $87.02 per share, expiring on September 16, 2036, vesting in one-third increments beginning on the first anniversary of the grant date.
He also received a restricted stock unit award of 4,597 units of common stock, vesting in equal one-third installments on each of the first, second and third anniversaries of the grant. After these awards, he holds 11,447 shares of common stock directly, plus 4,619 shares held through the issuer’s 401(k) plan trustee and 64,901 shares held indirectly through a trust. No Rule 10b5-1 trading plan is reported for these awards.
COLGATE PALMOLIVE CO (symbol: CL) is the issuer of record for a Form 4 filing submitted to the SEC. SUTULA STANLEY J III reported acquisition or exercise transactions in this Form 4 filing.
COLGATE PALMOLIVE CO (CL) reported that Chief Financial Officer Stanley J. Sutula III received new equity awards on September 16, 2026. He was granted 55,674 stock options to buy common shares at $87.02 per share, expiring September 16, 2036, and 8,045 restricted stock units that vest in three equal annual installments. Following these awards, he holds 79,029 common shares directly and 331 shares indirectly through the issuer’s 401(k) plan. No Rule 10b5-1 trading plan is reported.
COLGATE PALMOLIVE CO (CL) reported that Chief Growth Officer John Hazlin received equity awards on September 16, 2026. He was granted stock options for 27,042 shares of common stock at an exercise price of $87.02 per share, expiring September 16, 2036, which become exercisable in one-third increments beginning on the first anniversary of the grant date. He also received a restricted stock unit award of 3,908 shares that vests in equal one-third installments on each of the first, second and third anniversaries of the grant date. After these awards, he holds 27,021 common shares directly and 5,513 shares indirectly through the issuer’s 401(k) plan, and no Rule 10b5-1 trading plan is reported.
COLGATE PALMOLIVE CO (symbol: CL) is the issuer of record for a Form 4 filing submitted to the SEC. Massey Sally reported acquisition or exercise transactions in this Form 4 filing.
COLGATE PALMOLIVE CO (CL) reported that Chief People Officer Sally Massey received equity awards on September 16, 2026. She was granted 23,065 stock options to buy common shares at $87.02 per share, expiring September 16, 2036, and 3,333 restricted stock units that vest in three equal annual installments. After these awards, she holds 15,397 common shares directly and 8,199 common shares indirectly through the issuer’s 401(k) plan trustee, in addition to the new option grant. No Rule 10b5-1 trading plan is reported.
COLGATE PALMOLIVE CO (CL) reported that its CLO and Secretary, Betsy Fishbone, received equity awards on September 16, 2026. She was granted a stock option for 15,271 shares of common stock at an exercise price of $87.02 per share, expiring September 16, 2036, which becomes exercisable in one-third increments beginning on the first anniversary of the grant date.
She also received a restricted stock unit award of 2,207 shares that vests in equal one-third installments on each of the first, second, and third anniversaries of the grant date, increasing her directly held common stock to 16,050 shares. In addition, 50 common shares are held indirectly by a family member and 8,336 common shares are held indirectly through the issuer's 401(k) plan trustee.